# Why Do People Stop Taking a GLP-1? Cost Is the Commonest Reason | Buy This GLP

In a survey of 440 US adults who stopped a GLP-1, cost led at 36.1% and side effects followed at 33.3% | four in five stopped within twelve months.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/why-do-people-stop-taking-a-glp1
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# Why Do People Stop Taking a GLP-1? Cost Is the Commonest Reason

In 440 US adults who stopped, cost led at 36.1%, side effects followed at 33.3%, and four in five had stopped inside a year. Two of the top three reasons are about money.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20268 min readUpdated November 2026

Why 440 people stopped · cost · 36.1% · side effects · 33.3% · no coverage · 28.2% · goal reached · 26.1% · Two of the top three are about money.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   In a national survey of 440 US adults who stopped a GLP-1 drug, 54.6% stopped within six months and 79.7% within twelve.
-   The reasons given were cost (36.1%), side effects (33.3%), no insurance coverage (28.2%) and having reached a weight goal (26.1%).
-   Among respondents who had stopped, 17.5% who used a compounding pharmacy or online source cited perceived ineffectiveness, compared with 6.6% who used a retail or mail-order pharmacy.
-   The survey recorded patients’ perceptions. Researchers did not test the medications.

Cost, mostly. In a national survey of 440 US adults who had started and then stopped a GLP-1, cost led at 36.1%. Side effects followed at 33.3%, lack of insurance coverage at 28.2%, and reaching a weight goal at 26.1%. Two of the top three are about money rather than medicine. Four in five had stopped inside twelve months.

An Italian study of people offered self-pay liraglutide found that cost was a common reason to decline. The article on [why patients declined liraglutide](https://buythisglp.com/research/why-do-people-turn-down-a-glp1-prescription) describes that decision before treatment began [\[2\]](https://buythisglp.com/research/why-do-people-stop-taking-a-glp1#ref-2). In a separate US analysis, the [study of insurance and medication use](https://buythisglp.com/research/who-the-price-filtered-out) found lower odds of use among uninsured adults than among those with private insurance (odds ratio 0.53). Its estimate combined GLP-1 receptor agonists and SGLT2 inhibitors [\[3\]](https://buythisglp.com/research/why-do-people-stop-taking-a-glp1#ref-3). A separate [clinic study where medication was free](https://buythisglp.com/research/glp1-persistence-when-free) found a median of 10.7 months on treatment [\[4\]](https://buythisglp.com/research/why-do-people-stop-taking-a-glp1#ref-4). Each study measures a different decision about starting or continuing medication.

This site exists to compare sellers of compounded GLP-1 drugs. The study below contains a finding about those sellers that does not flatter them, and about the category this site makes its money from. It is here because a comparison that omits the uncomfortable result is not a comparison.

## Who was asked

Researchers screened 7,035 people and surveyed 440 US adults who had started and then stopped a GLP-1 receptor agonist [\[1\]](https://buythisglp.com/research/why-do-people-stop-taking-a-glp1#ref-1). Half were female, 42.3% were aged 18 to 34, and 23.8% had type 2 diabetes.

More than half — 54.6% — had stopped within six months of starting, and 79.7% within twelve among respondents who had already stopped. A separate [study of how long patients stayed on treatment](https://buythisglp.com/research/how-long-do-people-stay-on-a-glp1) also found frequent discontinuation within a year. The two studies report different estimates.

## Why they stopped

Cost was the most common reason at 36.1%, followed by side effects at 33.3%, lack of insurance coverage at 28.2%, and reaching a weight-loss goal at 26.1%. The [GLP-1 monthly cost guide](https://buythisglp.com/research/how-much-does-a-glp1-cost-per-month) explains how to add care fees and account for refills when estimating what you would pay.

Respondents with diabetes were significantly likelier than those without to stop because of side effects — 50.1% against 28.1%. How people paid was unusual too. Some 31.3% first filled a prescription without insurance at all. Another 35.4% used a copayment coupon, 22.0% a free sample, and 14.4% got the drug from a friend or family member.

Reasons for stopping by medication source

About one in five respondents sourced their medication from a compounding pharmacy (9.8%) or an internet-based seller (9.1%). Those respondents were significantly more likely to have stopped because they perceived the medication to be ineffective: 17.5% against 6.6% of people using a retail or mail-order pharmacy (p=0.009) [\[1\]](https://buythisglp.com/research/why-do-people-stop-taking-a-glp1#ref-1).

Respondents reported their reasons for stopping. The researchers did not test the products or establish whether medication source caused the difference.

## What could explain it

The survey did not establish which product or dose explained the difference. The [review of published dose and pricing terms](https://buythisglp.com/research/nobody-says-what-happens-at-a-higher-dose) examines what sellers disclose about higher doses. The review is based on listings and does not measure patient outcomes.

## What to do with it

When budgeting for ongoing treatment, use the [billed-price guide](https://buythisglp.com/research/glp1-headline-vs-billed-price) to identify which charges repeat after the introductory offer. Across the 158 injectable semaglutide prices in our catalog, the median monthly rate was $186 as of November 2026. At that rate, 12 months would cost $2,232.

Ask the provider what your prescribed dose would cost and whether a dose change would affect your next bill.

## Frequently asked

Why do people stop?

Cost (36.1%), side effects (33.3%), lack of insurance coverage (28.2%) and reaching a weight goal (26.1%). Two of the top three are about money rather than medicine.

How quickly do they stop?

54.6% within six months and 79.7% within twelve, in this survey of 440 people who had already discontinued.

Is compounded medication less effective?

The survey measured why respondents said they stopped. It did not test drug quality or compare effectiveness between formulations.

What can a buyer check beforehand?

Ask the provider what your prescribed dose costs and whether a dose change would affect the next bill.

## Sources

1.  \[1\] DiStefano MJ, et al. (2026). Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey Journal of Managed Care & Specialty Pharmacy. [PMID 42504813](https://pubmed.ncbi.nlm.nih.gov/42504813/)
2.  \[2\] Gilardini L, et al. (2026). Effectiveness of Liraglutide in Patients With Obesity Who Are Early Non-Responders to Lifestyle Intervention: A Real-World Study Journal of Obesity. [PMID 42658045](https://pubmed.ncbi.nlm.nih.gov/42658045/)
3.  \[3\] Jacobs M, Fang Q, Ellis C (2026). Trends in GLP-1 Receptor Agonist and SGLT2-Inhibitor Utilization and Expenditure Between 2017-2023: Demographic, Income, and Insurance Associations Journal of General Internal Medicine. [PMID 41984414](https://pubmed.ncbi.nlm.nih.gov/41984414/)
4.  \[4\] Samuels JM, et al. (2025). Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic Diabetes, Obesity and Metabolism. [PMID 40762026](https://pubmed.ncbi.nlm.nih.gov/40762026/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
